Acral Lentiginous Melanoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Acral Lentiginous Melanoma – Drugs In Development, 2024 report and make more profitable business decisions.
Acral lentiginous melanoma (ALM), also sometimes referred to as, simply, acral melanoma, is melanoma occurring on the hands and feet (palms, soles, fingers, toes, and nail units). This is is a subtype of cutaneous malignant melanoma. The condition can develop in normal-appearing skin or within an existing mole. It is comprised of malignant melanocytes, which can become invasive with time.
The Acral Lentiginous Melanoma drugs in development market research report provide comprehensive information on the therapeutics under development for Acral Lentiginous Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acral Lentiginous Melanoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Acral Lentiginous Melanoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 7 molecules, with 7 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Acral Lentiginous Melanoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Acral Lentiginous Melanoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Acral Lentiginous Melanoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aulos Bioscience IncGSK plc
Innovent Biologics Inc
Novartis AG
Plexxikon Inc
Regeneron Pharmaceuticals Inc
Tizona Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Acral Lentiginous Melanoma reports